Phenmetrazine was first patented in [[Germany]] in 1952 by [[Boehringer-Ingelheim]],<ref>{{cite news| first1= Albert| last1= Boehringer| first2= Ernst | last2= Boehringer| title= Improvements in or relating to the preparation of substituted morpholines| number= GB773780}}</ref><ref>{{cite patent| url= http://www.google.com/patents/US2835669 |country= US| status= Patent |title= Process for the Production of Substituted Morpholines | number= 2835669 | via= google.com| gdate= May 20, 1958| fdate= June 29, 1953| invent1= Otto Thoma| assign1= C. H. Boehringer Sohn}}</ref> with some pharmacological data published in 1954.<ref name= thomae>{{cite journal|last1= Thomä| first1= O |last2= Wick| first2= H |lastauthoramp=yes | title=Über einige Tetrahydro-1,4-oxazine mit sympathicomimetischen Eigenschaften| journal=Arch. Exp. Pathol. Pharmakol.| volume=222| year=1954| pages=540}}</ref> It was the result of a search by Thomä and Wick for an anorectic drug without the side-effects of [[amphetamine]].<ref name=martel>{{cite journal| last= Martel| first= Antonio| title=Preludin (Phenmetrazine) in the Treatment of Obesity| journal=Can. Med. Assoc. J.| volume=76| year=1957| pages=117–20| pmid=13383418| issue=2| pmc=1823494}}</ref> Phenmetrazine was introduced into [[Clinical trial|clinical]] use in 1954 in [[Europe]].<ref name=kalant>{{cite book| last= Kalant| first= Oriana Josseau| title=The Amphetamines: Toxicity and Addiction| year=1966| isbn=0-398-02511-8}}</ref>
